US 12,252,457 B2
Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
David D. Ginty, Boston, MA (US); Lauren L. Orefice, Boston, MA (US); and Jinbo Lee, Andover, MA (US)
Assigned to President and Fellows of Harvard College, Cambridge, MA (US)
Appl. No. 17/056,069
Filed by President and Fellows of Harvard College, Cambridge, MA (US)
PCT Filed May 22, 2019, PCT No. PCT/US2019/033581
§ 371(c)(1), (2) Date Nov. 17, 2020,
PCT Pub. No. WO2019/226808, PCT Pub. Date Nov. 28, 2019.
Claims priority of provisional application 62/823,360, filed on Mar. 25, 2019.
Claims priority of provisional application 62/674,770, filed on May 22, 2018.
Prior Publication US 2021/0206714 A1, Jul. 8, 2021
Int. Cl. C07C 229/48 (2006.01); A61P 25/02 (2006.01); A61P 25/04 (2006.01)
CPC C07C 229/48 (2013.01) [A61P 25/02 (2018.01); A61P 25/04 (2018.01)] 22 Claims
OG exemplary drawing
 
1. A compound having the structure of Formula (I):

OG Complex Work Unit Chemistry
wherein
n=1, 2, 3, 4, 5, 6, 7, or 8;
each of R1 and R2 is, independently, hydrogen, deuterium, optionally substituted C1-6 alkyl, or optionally substituted C3-6 cycloalkyl wherein R1 and R2 are covalently linked;
each R4 is, independently, hydrogen, deuterium, halogen, optionally substituted C1-4 alkoxy, optionally substituted C1-6 alkyl, CF3, CH3S, CH3SO2, or NO2; and
A is a carboxylic acid, or has the structure of:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof
wherein when A is a carboxylic acid, and each occurrence of R4 is hydrogen, at least one of R1 and R2 is not hydrogen.